# US 2010/0167989 A1 · Isopropoxyphenylmethyl inhibitors of sglt2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167989 A1
- Document ID: US20100167989A1
- Status: Published application
- Kind: A1
- Application number: 12/604,787
- Filed: 2009-10-23
- Published: 2010-07-01
- Earliest claimed: 2008-10-23
- Assignees: Auspex Pharmaceuticals, Inc.
- Inventors: Thomas G. Gant
- Web page: https://patentgrep.com/patent/US20100167989A1

## CPC

- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 38/28: Insulins
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07H 17/02: Heterocyclic radicals containing only nitrogen as ring hetero atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The present invention relates to new isopropoxyphenylmethyl inhibitors of SGLT2, pharmaceutical compositions thereof, and methods of use thereof.

## Claims

### Claim 1

A compound of structural Formula I
or a salt thereof, wherein:
R1 is selected from the group consisting of hydrogen, deuterium, and
R2-R39 are independently selected from the group consisting of hydrogen and deuterium; and
at least one of R1-R39 is deuterium.

### Claim 2 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R39 independently has deuterium enrichment of no less than about 10%.

### Claim 3 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R39 independently has deuterium enrichment of no less than about 50%.

### Claim 4 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R39 independently has deuterium enrichment of no less than about 90%.

### Claim 5 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R39 independently has deuterium enrichment of no less than about 98%.

### Claim 6 (depends on 1)

The compound as recited in claim 1 wherein said compound has a structural formula selected from the group consisting of

### Claim 7 (depends on 1)

The compound as recited in claim 1 wherein said compound has a structural formula selected from the group consisting of

### Claim 8 (depends on 7)

The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 10%.

### Claim 9 (depends on 7)

The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 50%.

### Claim 10 (depends on 7)

The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 90%.

### Claim 11 (depends on 7)

The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 98%.

### Claim 12 (depends on 7)

The compound as recited in claim 7 wherein said compound has the structural formula:

### Claim 13 (depends on 7)

The compound as recited in claim 7 wherein said compound has the structural formula:

### Claim 14 (depends on 7)

The compound as recited in claim 7 wherein said compound has the structural formula:

### Claim 15 (depends on 7)

The compound as recited in claim 7 wherein said compound has the structural formula:

### Claim 16 (depends on 7)

The compound as recited in claim 7 wherein said compound has the structural formula:

### Claim 17 (depends on 7)

The compound as recited in claim 7 wherein said compound has the structural formula:

### Claim 18 (depends on 1)

A pharmaceutical composition comprising a compound as recited in claim 1 together with a pharmaceutically acceptable carrier.

### Claim 19 (depends on 1)

A method of treatment of a SGLT2-mediated disorder comprising the administration of a therapeutically effective amount of a compound as recited in claim 1 to a patient in need thereof.

### Claim 20 (depends on 19)

The method as recited in claim 19 wherein said disorder is selected from the group consisting of type 1 diabetes, type 2 diabetes, obesity, and non-insulin dependent diabetes.

### Claim 21 (depends on 19)

The method as recited in claim 19 further comprising the administration of an additional therapeutic agent.

### Claim 22 (depends on 21)

The method as recited in claim 21 wherein said additional therapeutic agent is selected from the group consisting of dipeptidyl peptidase IV inhibitors, anti-diabetic agents, hypolipidemic agents, anti-obesity or appetite regulating agents, and anti-hypertensive agents.

### Claim 23 (depends on 21)

The method as recited in claim 21 wherein said additional therapeutic agent is a dipeptidyl peptidase IV inhibitor selected from the group consisting of vildagliptin, linagliptin, saxagliptin, sitagliptin, and alogliptin.

### Claim 24 (depends on 21)

The method as recited in claim 21 wherein said additional therapeutic agent is an anti-diabetic agent selected from the group consisting of include insulin, insulin derivatives, insulin mimetics, glipizide, glyburide, amaryl, nateglinide, repaglinide, PTP-112, 8B-517955, 8B4195052, 8B-216763, N,N-57-05441, N,N-57-05445, GW-0791, AGN-194204, T-1095, BAY R3401, metformin, acarbose, GLP-1, exendin-4, DPP728, MK-0431, G8K23A, glitazone, pioglitazone, rosiglitazone, (R)-1-{4-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-benzenesulfonyl}-2,3-dihydro-1H-indole-2-carboxylic acid, and GI-262570.

### Claim 25 (depends on 21)

The method as recited in claim 21 wherein said additional therapeutic agent is a hypolipidemic agent selected from the group consisting of lovastatin, pitavastatin, simvastatin, pravastatin, cerivastatin, mevastatin, velostatin, fluvastatin, dalvastatin, atorvastatin, rosuvastatin, rivastatin, cholestyramine, fibrates, nicotinic acid, and aspirin.

### Claim 26 (depends on 21)

The method as recited in claim 21 wherein said additional therapeutic agent is an anti-obesity or appetite-regulating agent selected from the group consisting of phentermine, leptin, bromocriptine, dexamphetamine, amphetamine, fenfluramine, dexfenfluramine, sibutramine, orlistat, dexfenfluramine, mazindol, phentermine, phendimetrazine, diethylpropion, fluoxetine, bupropion, topiramate, diethylpropion, benzphetamine, phenylpropanolamine, ecopipam, ephedrine, and pseudoephedrine.

### Claim 27 (depends on 21)

The method as recited in claim 21 wherein said additional therapeutic agent is an anti-hypertensive agent selected from the group consisting of ethacrynic acid, furosemide, torsemide, chlorithiazide, hydrochlorothiazide, amiloride, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perinodopril, quinapril, ramipril, trandolapril, digoxin, thiorphan, terteo-thiorphan, SQ29072, SLV306, omapatrilat, sampatrilat, fasidotril, candesartan, eprosartan, irbesartan, losartan, telmisartan, valsartan, aliskiren, terlakiren, ditekiren, RO-66-1132, RO-66-1168, acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, sotalol, timolol, digoxin, dobutamine, milrinone, amlodipine, bepridil, diltiazem, felodipine, nicardipine, nimodipine, nifedipine, nisoldipine, and verapamil.

### Claim 28 (depends on 21)

The method as recited in claim 21 wherein said additional therapeutic agent is metaformin.

### Claim 29 (depends on 19)

The method as recited in claim 19, further resulting in at least one effect selected from the group consisting of:
a. decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound;
b. increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
c. decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
d. increased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; and
e. an improved clinical effect during the treatment in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

### Claim 30 (depends on 19)

The method as recited in claim 19, further resulting in at least two effects selected from the group consisting of:
a. decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound;
b. increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
c. decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
d. increased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; and
e. an improved clinical effect during the treatment in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

### Claim 31 (depends on 19)

The method as recited in claim 19, wherein the method effects a decreased metabolism of the compound per dosage unit thereof by at least one polymorphically-expressed cytochrome P450 isoform in the subject, as compared to the corresponding non-isotopically enriched compound.

### Claim 32 (depends on 31)

The method as recited in claim 31, wherein the cytochrome P450 isoform is selected from the group consisting of CYP2C8, CYP2C9, CYP2C19, and CYP2D6.

### Claim 33 (depends on 19)

The method as recited claim 19, wherein said compound is characterized by decreased inhibition of at least one cytochrome P450 or monoamine oxidase isoform in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

### Claim 34 (depends on 33)

The method as recited in claim 33, wherein said cytochrome P450 or monoamine oxidase isoform is selected from the group consisting of CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2G1, CYP2J2, CYP2R1, CYP2S1, CYP3A4, CYP3A5, CYP3A5P1, CYP3A5P2, CYP3A7, CYP4A11, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12, CYP4×1, CYP4Z1, CYP5A1, CYP7A1, CYP7B1, CYP8A1, CYP8B1, CYP11A1, CYP11B1, CYP11B2, CYP17, CYP19, CYP21, CYP24, CYP26A1, CYP26B1, CYP27A1, CYP27B1, CYP39, CYP46, CYP51, MAOA, and MAOB.

### Claim 35 (depends on 19)

The method as recited in claim 19, wherein the method reduces a deleterious change in a diagnostic hepatobiliary function endpoint, as compared to the corresponding non-isotopically enriched compound.

### Claim 36 (depends on 35)

The method as recited in claim 35, wherein the diagnostic hepatobiliary function endpoint is selected from the group consisting of alanine aminotransferase (“ALT”), serum glutamic-pyruvic transaminase (“SGPT”), aspartate aminotransferase (“AST,” “SGOT”), ALT/AST ratios, serum aldolase, alkaline phosphatase (“ALP”), ammonia levels, bilirubin, gamma-glutamyl transpeptidase (“GGTP,” “γ-GTP,” “GGT”), leucine aminopeptidase (“LAP”), liver biopsy, liver ultrasonography, liver nuclear scan, 5′-nucleotidase, and blood protein.

### Claim 37 (depends on 1)

A compound as recited in claim 1 for use as a medicament.

### Claim 38 (depends on 1)

A compound as recited in claim 1 for use in the manufacture of a medicament for the prevention or treatment of a disorder ameliorated by the inhibition of SGLT2.
